Caregen Co.Ltd Asset Resilience Ratio

Latest as of June 2025: 4.58%

Caregen Co.Ltd asset resilience ratio. Caregen Co.Ltd (214370) has an Asset Resilience Ratio of 4.58% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Caregen Co.Ltd fund operations to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩10.72 Billion
≈ $7.26 Million USD Cash + Short-term Investments

Total Assets

₩233.98 Billion
≈ $158.57 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Caregen Co.Ltd (2015–2024)

Asset resilience ratio of Caregen Co.Ltd from 2015 to 2024. This chart shows how Caregen Co.Ltd's Asset Resilience Ratio has changed over time. Read 214370 current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Caregen Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 214370 current and non-current assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩10.72 Billion 4.58%
Total Liquid Assets ₩10.72 Billion 4.58%

Asset Resilience Insights

  • Limited Liquidity: Caregen Co.Ltd maintains only 4.58% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Caregen Co.Ltd Industry Peers by Asset Resilience Ratio

Compare Caregen Co.Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
GeneBioTech Co. Ltd
KQ:086060
Pharmaceuticals 22.68%
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
Pharmaceuticals 6.87%
ST Pharm Co.Ltd
KQ:237690
Pharmaceuticals 7.72%
NatureCell Co.Ltd
KQ:007390
Pharmaceuticals 0.00%
Oscotec Inc
KQ:039200
Pharmaceuticals 66.73%
Komipharm International Co. Ltd
KQ:041960
Pharmaceuticals 0.00%
Mezzion Pharma Co.Ltd
KQ:140410
Pharmaceuticals 0.00%
Aprogen Healthcare & Games Inc
KQ:109960
Pharmaceuticals 6.55%

Caregen Co.Ltd Asset Resilience Ratio by Year (2015–2024)

Caregen Co.Ltd asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Caregen Co.Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 18.38% ₩44.25 Billion
≈ $29.99 Million
₩240.70 Billion
≈ $163.12 Million
-35.29pp
2023-12-31 53.67% ₩132.71 Billion
≈ $89.94 Million
₩247.28 Billion
≈ $167.58 Million
-6.34pp
2022-12-31 60.01% ₩140.48 Billion
≈ $95.20 Million
₩234.07 Billion
≈ $158.63 Million
-0.08pp
2021-12-31 60.09% ₩136.26 Billion
≈ $92.34 Million
₩226.76 Billion
≈ $153.67 Million
+1.16pp
2020-12-31 58.93% ₩127.62 Billion
≈ $86.49 Million
₩216.56 Billion
≈ $146.76 Million
-13.27pp
2019-12-31 72.20% ₩167.39 Billion
≈ $113.44 Million
₩231.85 Billion
≈ $157.12 Million
+0.64pp
2018-12-31 71.56% ₩156.68 Billion
≈ $106.18 Million
₩218.94 Billion
≈ $148.37 Million
+28.91pp
2017-12-31 42.65% ₩105.35 Billion
≈ $71.40 Million
₩247.02 Billion
≈ $167.40 Million
-27.89pp
2016-12-31 70.54% ₩175.73 Billion
≈ $119.09 Million
₩249.13 Billion
≈ $168.83 Million
+37.37pp
2015-12-31 33.17% ₩85.08 Billion
≈ $57.66 Million
₩256.52 Billion
≈ $173.84 Million
--
pp = percentage points

About Caregen Co.Ltd

KQ:214370 Korea Pharmaceuticals
Market Cap
$196.57 Million
₩290.06 Billion KRW
Market Cap Rank
#16408 Global
#600 in Korea
Share Price
₩27000.00
Change (1 day)
-2.35%
52-Week Range
₩27000.00 - ₩150100.00
All Time High
₩150100.00
About

Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG S… Read more